
Aura Biosciences (AURA) Stock Forecast & Price Target
Aura Biosciences (AURA) Analyst Ratings
Bulls say
Aura Biosciences Inc is demonstrating promising advancements in its late-stage clinical development of bel-sar, evidenced by significantly superior patient outcomes in those receiving the full therapeutic regimen compared to subtherapeutic cohorts. The delivery method for bel-sar has shown a five-fold increase in tumor exposure while simultaneously reducing off-target toxicity, suggesting enhanced efficacy and safety profiles. Additionally, the positive visual function outcomes further highlight the clinical value of bel-sar, supporting a strong foundation for future growth and potential market uptake in targeted cancer treatments.
Bears say
Aura Biosciences Inc. has reported a significant reduction in the tumor growth rate among patients receiving treatment, from 0.555 mm/year pre-treatment to 0.072 mm/year post-treatment, indicating some treatment efficacy; however, this improvement is not sufficient to ensure financial stability. The company has experienced ongoing operating losses since its inception, with projections suggesting that it may not achieve profitability for several years, raising concerns about its cash flow and long-term viability. Additionally, the potential for failure to secure regulatory approvals or delays in the development timelines could further exacerbate the negative outlook for the company’s share price.
This aggregate rating is based on analysts' research of Aura Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Aura Biosciences (AURA) Analyst Forecast & Price Prediction
Start investing in Aura Biosciences (AURA)
Order type
Buy in
Order amount
Est. shares
0 shares